Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript excerpts. The company is focusing on balance sheet discipline and has reduced net debt by Rs. 169 crores on a constant currency basis over 9 months. Net debt stands at Rs. 1,436 crores with an improved EBITDA to net debt ratio of 1.59x, indicating strengthening financial health. The company invested Rs. 284 crores in CAPEX and product rights, funded through operational cash flows (operating cash of Rs. 484 crores over 9 months). Management emphasizes improving profitabi

Any current/future capex/capital investment/strategic investment?

Maintenance CAPEX is on track in the range of Rs. 100 crore to Rs. 125 crore. Additional CAPEX includes opportunistic targeted purchases of global rights for both US and Ex-US markets, though no specific numbers are provided. Rs. 284 crores invested in CAPEX for tangible and intangible assets during the 9-month period. Investments are aimed at driving growth in both the US and Ex-US markets. The company plans to continue investing in R&D programs, expected to start delivering revenue in the next 12 to 18 months. Focus remains on balancing CAPEX between maintenance and growth opportunities with

Future growth expectations in sales/revenue/volumes?

Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters. Ex-US markets (other regulated and growth markets) are growing faster than anticipated, now contributing 47% of Q3 FY'26 revenues with 20% YoY growth; the gap between US and Ex-US revenues has significantly narrowed. Growth drivers include ramping up dormant products, control substances normalizing, investing in complex generics like nasal sprays and 505(b)(2) programs, and expanding product portfolios within existing geographies. The company foresees consisten

Future growth expectations in earnings/operating earnings/profits/EPS?

The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years. Operational PAT grew 65% in the 9-month period with an operational EPS of Rs. 41.5, already exceeding FY'25 full-year operational PAT. EBITDA margins have improved by 180 basis points from FY'25 and operating leverage is expected to continue as under-recoveries reduce. Focus remains on EBITDA margin expansion, with profitability thresholds guiding product portfolio decisions. Tax rate is expected to be in the 15% to 20% range over the next couple of years. Investments in R&D, p

Current/ Expected Orderbook/ Pending Orders?

Order book in access market currently subdued due to reduced donor funding, especially from large institutions like the Global Fund. Several countries have lowered their contributions, causing a significant reduction in orders not only for Strides but industry-wide. Allocation periods are rolling over as donors have not fulfilled obligations. Some countries are increasing contributions to fill funding gaps caused by others, but the gap remains large. Near-term outlook for access market orders is muted. Expectation that donor funding and order volumes will improve or "ameliorate" gradually in t

IN US

Sale is live|00:00:00left today

Strides Pharma Science LtdQ4 FY27Pharmaceuticals & Biotechnology

Strides Pharma Science Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,056P/E: 19.4Market Cap: ₹10.6K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3

→Strides Pharma aims to achieve around $400 million revenue from the US market by FY'28, with growth expected over the next 9 quarters.
→Ex-US markets (other regulated and growth markets) are growing faster than anticipated, now contributing 47% of Q3 FY'26 revenues with 20% YoY growth; the gap between US and Ex-US revenues has significantly narrowed.
→Growth drivers include ramping up dormant products, control substances normalizing, investing in complex generics like nasal sprays and 505(b)(2) programs, and expanding product portfolios within existing geographies.
→The company foresees consistent growth rather than quarter-to-quarter spikes, with multiple levers in place across markets.
→Planned launches and portfolio expansions will sustain growth; the focus remains on profitability and EBITDA margin expansion.
→The regulatory pathway and customer base in Ex-US markets are mature, supporting steady growth.
→Industry-wide pricing pressure remains, but improved cost of goods sold helps maintain margins.

Margin guidance

Category 3

→The company aims to reach US revenues of $400 million by FY'28 with consistent growth expected over the next 2 years.
→Operational PAT grew 65% in the 9-month period with an operational EPS of Rs. 41.5, already exceeding FY'25 full-year operational PAT.
→EBITDA margins have improved by 180 basis points from FY'25 and operating leverage is expected to continue as under-recoveries reduce.
→Focus remains on EBITDA margin expansion, with profitability thresholds guiding product portfolio decisions.
→Tax rate is expected to be in the 15% to 20% range over the next couple of years.
→Investments in R&D, product acquisitions, and expansion in ex-US regulated markets are key drivers.
→Operational PAT margin for the quarter was at 10.7%, with continued focus on balancing growth and profitability.
→The company expects consistent growth from Ex-US markets and a steady ramp-up from the US business driven by dormant products and control substances normalizing.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or future fundraising plans through debt or equity in the provided transcript excerpts.
→The company is focusing on balance sheet discipline and has reduced net debt by Rs. 169 crores on a constant currency basis over 9 months.
→Net debt stands at Rs. 1,436 crores with an improved EBITDA to net debt ratio of 1.59x, indicating strengthening financial health.
→The company invested Rs. 284 crores in CAPEX and product rights, funded through operational cash flows (operating cash of Rs. 484 crores over 9 months).
→Management emphasizes improving profitability and maintaining targeted debt/EBITDA ratios but does not discuss raising fresh funds via debt or equity.
→Overall, priority is on sustainable growth and balance sheet strength rather than immediate external fundraising.

Order book

→Order book in access market currently subdued due to reduced donor funding, especially from large institutions like the Global Fund.
→Several countries have lowered their contributions, causing a significant reduction in orders not only for Strides but industry-wide.
→Allocation periods are rolling over as donors have not fulfilled obligations.
→Some countries are increasing contributions to fill funding gaps caused by others, but the gap remains large.
→Near-term outlook for access market orders is muted.
→Expectation that donor funding and order volumes will improve or "ameliorate" gradually in the near future.

Capex plans

Yes

→Maintenance CAPEX is on track in the range of Rs. 100 crore to Rs. 125 crore.
→Additional CAPEX includes opportunistic targeted purchases of global rights for both US and Ex-US markets, though no specific numbers are provided.
→Rs. 284 crores invested in CAPEX for tangible and intangible assets during the 9-month period.
→Investments are aimed at driving growth in both the US and Ex-US markets.
→The company plans to continue investing in R&D programs, expected to start delivering revenue in the next 12 to 18 months.
→Focus remains on balancing CAPEX between maintenance and growth opportunities without compromising on profitability.

How does Strides Pharma Science Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Strides Pharma Science Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Strides Pharma Science Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio